Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.

J Clin Oncol. 2019 Dec 27:JCO1900895. doi: 10.1200/JCO.19.00895. [Epub ahead of print]


Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.

Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT.

Leukemia. 2019 Dec 16. doi: 10.1038/s41375-019-0688-1. [Epub ahead of print] No abstract available.


Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, Watanabe-Smith K, Jeng S, Smith JL, Leonti AR, Ries RE, McWeeney S, Di Genua C, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE.

Nat Commun. 2019 Nov 29;10(1):5455. doi: 10.1038/s41467-019-13364-2.


Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.


A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE.

Cancer Res. 2018 Dec 15;78(24):6762-6770. doi: 10.1158/0008-5472.CAN-18-1638. Epub 2018 Oct 22.


Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.

Sci Signal. 2018 Jul 17;11(539). pii: eaao5617. doi: 10.1126/scisignal.aao5617.


Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW.

J Biol Chem. 2018 May 11;293(19):7387-7396. doi: 10.1074/jbc.RA118.002417. Epub 2018 Mar 23.


Recurrent cyclin D2 mutations in myeloid neoplasms.

Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW.

Leukemia. 2017 Sep;31(9):2005-2008. doi: 10.1038/leu.2017.195. Epub 2017 Jun 20. No abstract available.


Genomics of chronic neutrophilic leukemia.

Maxson JE, Tyner JW.

Blood. 2017 Feb 9;129(6):715-722. doi: 10.1182/blood-2016-10-695981. Epub 2016 Dec 27. Review.


CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.

Maxson JE, Ries RE, Wang YC, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Hughes SB, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, Meshinchi S.

Blood. 2016 Jun 16;127(24):3094-8. doi: 10.1182/blood-2016-04-709899. Epub 2016 May 3. No abstract available. Erratum in: Blood. 2017 Jan 5;129(1):134.


Neogenin Facilitates the Induction of Hepcidin Expression by Hemojuvelin in the Liver.

Zhao N, Maxson JE, Zhang RH, Wahedi M, Enns CA, Zhang AS.

J Biol Chem. 2016 Jun 3;291(23):12322-35. doi: 10.1074/jbc.M116.721191. Epub 2016 Apr 12.


Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.

Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, Gray NS, Druker BJ, Tyner JW.

Cancer Res. 2016 Jan 1;76(1):127-38. doi: 10.1158/0008-5472.CAN-15-0817. Epub 2015 Dec 17.


The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide CA, Loriaux MM, Stevens EA, Tyner JW.

Clin Cancer Res. 2016 Feb 1;22(3):757-64. doi: 10.1158/1078-0432.CCR-14-3100. Epub 2015 Oct 16.


Therapeutically Targetable ALK Mutations in Leukemia.

Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW.

Cancer Res. 2015 Jun 1;75(11):2146-50. doi: 10.1158/0008-5472.CAN-14-1576.


Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.

Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE, Traer E.

Leuk Res Rep. 2014 Dec 25;4(1):8-11. doi: 10.1016/j.lrr.2014.12.003. eCollection 2015.


Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW.

Leuk Res Rep. 2014 Aug 1;3(2):67-9. doi: 10.1016/j.lrr.2014.07.002. eCollection 2014.


Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.

Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW.

J Biol Chem. 2014 Feb 28;289(9):5820-7. doi: 10.1074/jbc.M113.508440. Epub 2014 Jan 8.


The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW.

Blood. 2013 Nov 21;122(22):3628-31. doi: 10.1182/blood-2013-06-509976. Epub 2013 Sep 30.


The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Gotlib J, Maxson JE, George TI, Tyner JW.

Blood. 2013 Sep 5;122(10):1707-11. doi: 10.1182/blood-2013-05-500959. Epub 2013 Jul 29. Review.


Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.

Braun TP, Grossberg AJ, Krasnow SM, Levasseur PR, Szumowski M, Zhu XX, Maxson JE, Knoll JG, Barnes AP, Marks DL.

FASEB J. 2013 Sep;27(9):3572-82. doi: 10.1096/fj.13-230375. Epub 2013 Jun 3.


Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW.

N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.


CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A.

Leukemia. 2013 Sep;27(9):1870-3. doi: 10.1038/leu.2013.122. Epub 2013 Apr 22.


Expression of myeloid differentiation factor 88 in neurons is not requisite for the induction of sickness behavior by interleukin-1β.

Braun TP, Grossberg AJ, Veleva-Rotse BO, Maxson JE, Szumowski M, Barnes AP, Marks DL.

J Neuroinflammation. 2012 Oct 3;9:229. doi: 10.1186/1742-2094-9-229.


Matriptase-2- and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression.

Maxson JE, Chen J, Enns CA, Zhang AS.

J Biol Chem. 2010 Dec 10;285(50):39021-8. doi: 10.1074/jbc.M110.183160. Epub 2010 Oct 11.


The cell giveth and the cell taketh away: an overview of Notch pathway activation by endocytic trafficking of ligands and receptors.

Pratt EB, Wentzell JS, Maxson JE, Courter L, Hazelett D, Christian JL.

Acta Histochem. 2011 May;113(3):248-55. doi: 10.1016/j.acthis.2010.01.006. Epub 2010 Feb 1. Review.


Processing of hemojuvelin requires retrograde trafficking to the Golgi in HepG2 cells.

Maxson JE, Enns CA, Zhang AS.

Blood. 2009 Feb 19;113(8):1786-93. doi: 10.1182/blood-2008-08-174565. Epub 2008 Nov 24.

Supplemental Content

Loading ...
Support Center